Reversible electropermeabilisation of human and rat blood platelets: evaluation of morphological and functional integrity 'in vitro' and 'in vivo'.
A high-voltage discharge procedure has been developed for permeabilising the plasma membranes of both human and rat blood platelets. The cells can be resealed by incubation at 37 degrees C, show less than 4% loss of lactate dehydrogenase (LDH) implying minimal cell lysis and also have well maintained morphological and functional integrity. The prototype apparatus used at field strengths between 6 and 8 kV/cm produces membrane pores which allow free diffusion of low molecular weight substances such as adenine nucleotides, inositol phosphate and fluorescent dyes. Two properties, namely Ca2+-induced secretion of granule stored 5-hydroxytryptamine (5HT) and inositol 1,4,5-trisphosphate (IP3)-induced release of intracellularly sequestered 45Ca, which are both well expressed immediately after permeabilisation, are essentially abolished after resealing. The efficiency of permeabilisation and resealing can be simply monitored by shifts in 'apparent platelet volume' using a resistive particle counter (Coulter). Permeabilised platelets show a shift in modal volumes from a control range 4-7 fl to 10-15 fl. Resealing restores these modal volumes to the original control range. Encapsulation of the fluorochrome, Lucifer yellow (Mr 550), during permeabilisation revealed that after resealing greater than 85% of rat platelets, and close to 100% human platelets, contained the encapsulated dye. The initial rates and % aggregation responses of both human and rat platelets to collagen, thrombin and the thromboxane A2-mimetic U46619 remained essentially normal after permeabilisation and resealing further illustrating the maintenance of functional competence following treatment. Resealed rat platelets reinfused into the circulation after labelling with [111In]indium oxine gave survival curves similar to those of control platelets. Therefore, this reversible permeabilisation procedure may allow the use of autologous or heterologous platelets as carrier vehicles for the delivery of drugs and other agents 'in vivo'.
Hughes
K
K
Department of Biochemistry and Cell Biology, Hunterian Institute, Royal College of Surgeons of England, London, U.K.
Crawford
N
N
D000227:Adenine Nucleotides / Q000097:blood; D000818:Animals; D001792:Blood Platelets / Q000502:physiology* / Q000648:ultrastructure; D002463:Cell Membrane Permeability; D004560:Electricity; D006801:Humans; D066298:In Vitro Techniques; D007546:Isoquinolines; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008855:Microscopy, Electron, Scanning; D014677:Pharmaceutical Vehicles; D010974:Platelet Aggregation; D051381:Rats; D012701:Serotonin / Q000378:metabolism
D000227:Adenine Nucleotides; D007546:Isoquinolines; D014677:Pharmaceutical Vehicles; D012701:Serotonin; C017475:lucifer yellow; D007770:L-Lactate Dehydrogenase